Ozempic Feet is an informal term used to describe changes in the appearance of the feet following significant weight loss, particularly in people taking medications such as Ozempic or Wegovy (semaglutide). Similar to the better-known term “Ozempic Face”, Ozempic Feet refers to the loss of fatty tissue beneath the skin, which can make the feet appear thinner, bonier, more wrinkled, and sometimes older. It is not an officially recognised medical diagnosis, nor is it a proven direct side effect of semaglutide. Instead, the changes are generally attributed to substantial or rapid weight loss, which can reduce fat deposits throughout the body, including those in the feet.
One of the main concerns associated with Ozempic Feet is the potential loss of protective fat padding on the soles of the feet, particularly beneath the heels and the balls of the feet. These specialised fat pads act as natural shock absorbers, cushioning the bones and joints during walking, standing, and running. If this padding becomes thinner or less effective, individuals may experience increased pressure beneath the metatarsal heads, heel discomfort, or a sensation of walking directly on their bones. This condition is sometimes referred to as plantar fat pad atrophy. However, there is currently limited scientific evidence demonstrating that Ozempic specifically causes plantar fat pad atrophy, and changes in foot cushioning should not automatically be attributed to weight-loss medication.
Other changes associated with significant weight loss can include more prominent tendons and veins on the tops of the feet, looser skin, and alterations in shoe fit. As overall body weight decreases, the feet may also become narrower or slightly smaller, potentially requiring different footwear sizes. Interestingly, weight loss can also have substantial benefits for foot health, as reducing body weight decreases the mechanical load placed on the feet and lower limbs. This may help relieve symptoms associated with plantar fasciitis, osteoarthritis, and other weight-related foot problems. Therefore, although some people may notice cosmetic changes or reduced cushioning, weight loss does not necessarily lead to increased foot pain.
Managing Ozempic Feet depends on whether the changes are purely cosmetic or are causing discomfort. For people experiencing pain beneath the heels or forefoot, cushioned footwear, shock-absorbing insoles, heel cups, and appropriately positioned metatarsal pads may help redistribute pressure and improve comfort. A podiatrist can assess whether genuine fat pad atrophy is present and distinguish it from conditions such as plantar fasciitis, metatarsalgia, or peripheral neuropathy. Maintaining adequate nutrition, preserving muscle mass through resistance exercise, and avoiding unnecessarily rapid weight loss may also support overall musculoskeletal health. Importantly, anyone taking Ozempic who develops new foot pain, numbness, or significant changes in their feet should seek professional assessment rather than assuming these symptoms are simply a consequence of weight loss.
The key distinction: Ozempic Feet is primarily a popular description of changes in foot appearance following weight loss, rather than an established medication-related foot disorder. There is not yet strong clinical evidence linking semaglutide directly to loss of the specialised plantar fat pads.